Urolithin A is a postbiotic small molecule derived from ellagitannin metabolism and is a key regulator of mitochondrial quality control through mitophagy induction.
Due to variability in endogenous production arising from differences in gut microbiota, our program focuses on the synthetic production of high-purity Urolithin A to ensure consistent quality, reproducibility, and scalable supply.
Our development strategy emphasizes robust synthetic routes, stringent control of phenolic and lactone-related impurities, and manufacturing processes aligned with clinical and commercial supply requirements.
"Aurapha’s science-driven approach to API development demonstrates how rigorous chemistry, process robustness, and regulatory readiness can translate complex molecules into reliable, scalable drug substances."